AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.

The firm will stop shipping the gene therapy for these patients until a new immunosuppressive regimen is approved for managing acute liver failure.

Wall Street analysts were quick to downgrade Sarepta Therapeutics (NASDAQ:SRPT) on Monday as the company suspended its revenue guidance for 2025 following a second fatality linked to Elevidys, its ...

A second case of acute liver failure (ALF) resulting in the death has been reported in a young recipient of Elevidys ...

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has ...

Sarepta Therapeutics Inc. plummeted in early trading after reporting a second patient died of acute liver failure while being treated with its gene therapy for a rare muscle disorder.

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain ...

Gucci Owner Picks Auto Executive for One of Global Luxury's Top Jobs Francois-Henri Pinault is stepping back as CEO of Kering, hoping Luca de Meo can pull Gucci and Saint Laurent out of a slump.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...